Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production
Authors
Keywords
-
Journal
Diabetes Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-26
DOI
10.1007/s13300-023-01491-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms
- (2023) Elena Osto et al. PHARMACOLOGICAL RESEARCH
- Normal HDL cholesterol efflux and anti-inflammatory capacities in type 2 diabetes despite lipidomic abnormalities
- (2022) Damien Denimal et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
- (2022) Hao Zhaohu et al. Journal of Diabetes Research
- Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
- (2022) Lucia Leccisotti et al. Cardiovascular Diabetology
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options
- (2022) Teresa Salvatore et al. Biomedicines
- Impaired coronary flow reserve in patients with poor type 2 diabetes control: Preliminary results from prospective microvascular dysfunction registry
- (2022) Łukasz Niewiara et al. Cardiology Journal
- Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
- (2021) Gian Pio Sorice et al. Diabetes Therapy
- Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
- (2021) Andrea Natali et al. Cardiovascular Diabetology
- LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters
- (2020) Lorenzo Arnaboldi et al. ATHEROSCLEROSIS
- The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol
- (2020) Kristien E. C. Bouter et al. DIABETES OBESITY & METABOLISM
- Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials
- (2020) Adriana Sánchez-García et al. PHARMACOLOGICAL RESEARCH
- Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome
- (2019) Alice Ossoli et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Sodium‐glucose co‐transporter inhibitors: Medications that mimic fasting for cardiovascular prevention
- (2019) Andrea Giaccari DIABETES OBESITY & METABOLISM
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dysfunctional HDL as a therapeutic target for atherosclerosis prevention
- (2018) Alice Ossoli et al. CURRENT MEDICINAL CHEMISTRY
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- (2015) Nobuya Inagaki et al. ADVANCES IN THERAPY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol Efflux and Atheroprotection
- (2012) Robert S. Rosenson et al. CIRCULATION
- Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials
- (2011) Martin K Reriani et al. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
- (2010) Laura Calabresi et al. CURRENT PHARMACEUTICAL DESIGN
- Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy
- (2009) Sajoscha A. Sorrentino et al. CIRCULATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now